

Stephen J Freedland

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6273759/stephen-j-freedland-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

336
papers

9,901
citations

54
h-index

91
g-index

374
ext. papers

12,100
ext. citations

4.8
avg, IF

6.23
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 336 | Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100097 | 5.2 | 1 |
| 335 | Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement.. <i>Cancer Causes and Control</i> , 2022 , 33, 613 | 2.8 | 1 |
| 334 | The DNA damage repair landscape in Black women with breast cancer.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221075458 | 5.4 | 1 |
| 333 | A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. <i>International Journal of Cancer</i> , 2022 , 150, 80-90 | 7.5 | 2 |
| 332 | First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. <i>Drugs</i> , 2022 , 82, 439 | 12.1 | 0 |
| 331 | Identification of muscle-invasion status in bladder cancer patients using natural language processing and machine learning.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 447-447 | 2.2 | |
| 330 | Long-term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 455-455 | 2.2 | |
| 329 | Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 527-527 | 2.2 | |
| 328 | HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 370-370 | 2.2 | |
| 327 | Prostate-specific antigen (PSA) outcomes in black (B) and white (W) chemotherapy-naïve (CN) prostate cancer (PC) patients (pts) treated with enzalutamide (ENZA).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 20-20 | 2.2 | |
| 326 | Abstract P3-14-03: The DNA damage repair landscape in Black women with breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-14-03-P3-14-03 | 10.1 | |
| 325 | Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.. <i>Journal of Urology</i> , 2022 , 101097JU00000000000002675 | 2.5 | |
| 324 | QOLP-04. THE KETOGENIC DIET PLUS STANDARD CARE FOR RECENTLY DIAGNOSED GLIOBLASTOMA: A PHASE 1 SAFETY AND FEASIBILITY TRIAL. <i>Neuro-Oncology</i> , 2021 , 23, vi183-vi183 | 1 | 0 |
| 323 | QOLP-20. DIETARY, ACTIVITY, AND QUALITY OF LIFE METRICS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA IMPLEMENTING A KETOGENIC DIET: RESULTS OF A PHASE 1 CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021 , 23, vi187-vi187 | 1 | |
| 322 | Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer. <i>Journal of Urology</i> , 2021 , 101097JU00000000000002256 | 2.5 | 0 |
| 321 | Epidemiology and Prevention of Prostate Cancer. <i>European Urology Oncology</i> , 2021 , | 6.7 | 20 |
| 320 | Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. <i>Cancer Medicine</i> , 2021 , 10, 8570-8580 | 4.8 | 3 |

| | | | |
|-----|---|------|----|
| 319 | Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. <i>Prostate</i> , 2021 , 81, 390-397 | 4.2 | 1 |
| 318 | Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. <i>Journal of Urology</i> , 2021 , 205, 755-765 | 2.5 | 1 |
| 317 | Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab023 | 4.6 | 1 |
| 316 | Epidemiology and genomics of prostate cancer in Asian men. <i>Nature Reviews Urology</i> , 2021 , 18, 282-301 | 5.5 | 24 |
| 315 | Comorbidities in a Nationwide, Heterogenous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome. <i>Urology</i> , 2021 , 156, 37-43 | 1.6 | 1 |
| 314 | The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer. <i>Prostate</i> , 2021 , 81, 618-628 | 4.2 | 3 |
| 313 | Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5074-5074 | 2.2 | 4 |
| 312 | Prevalence of potential drug-drug interactions among nonmetastatic castration-resistant prostate cancer patients treated with apalutamide and enzalutamide.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e18690-e18690 | 2.2 | 0 |
| 311 | Smoking Is Associated With Basal Cell Hyperplasia on Prostate Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 934-938 | 1.9 | |
| 310 | Diagnostic Utility of Serum and Urinary Metabolite Analysis in Patients with Interstitial Cystitis/Painful Bladder Syndrome. <i>Urology</i> , 2021 , | 1.6 | 2 |
| 309 | DNA mismatch repair and microsatellite instability in colorectal tumors: An observational study in the Veterans Affairs Health Care System.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e15562-e15562 | 2.2 | 0 |
| 308 | Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5073-5073 | 2.2 | 2 |
| 307 | Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort. <i>JAMA Network Open</i> , 2021 , 4, e2112214 | 10.4 | 0 |
| 306 | Implications of Regionalizing Care in the Developing World: Impact of Distance to Referral Center on Compliance to Biopsy Recommendations in a Brazilian Prostate Cancer Screening Cohort. <i>Prostate Cancer</i> , 2021 , 2021, 6614838 | 1.9 | |
| 305 | Patients' Preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 367.e7-367.e17 | 2.8 | 0 |
| 304 | Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial. <i>Journal of Urology</i> , 2021 , 205, 1733-1739 | 2.5 | 2 |
| 303 | The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting. <i>Cancer</i> , 2021 , 127, 3998-4005 | 6.4 | 1 |
| 302 | Association between metformin medication, genetic variation and prostate cancer risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 96-105 | 6.2 | 7 |

| | | | |
|-----|--|------|----|
| 301 | Partial Validation of the Sleep Health Construct in the Medical Outcomes Study Sleep Questionnaire. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021 , 28, 168-173 | 2 | |
| 300 | Public interest in dietary supplements for prostate cancer prevention. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 58-60 | 6.2 | |
| 299 | Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 320-329 | 12.9 | 19 |
| 298 | A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021 , 79, 374-383 | 10.2 | 28 |
| 297 | Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. <i>Urology</i> , 2021 , 149, 181-186 | 1.6 | 0 |
| 296 | Posttraumatic stress disorder and suicide among veterans with prostate cancer. <i>Psycho-Oncology</i> , 2021 , 30, 581-590 | 3.9 | 0 |
| 295 | The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 335-340 | 6.2 | 2 |
| 294 | Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer. <i>Urology Practice</i> , 2021 , 8, 112-118 | 0.8 | 1 |
| 293 | A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma. <i>Cancer Research</i> , 2021 , 81, 1216-1229 | 10.1 | 8 |
| 292 | Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database. <i>Cancer Causes and Control</i> , 2021 , 32, 189-197 | 2.8 | 0 |
| 291 | Androgen deprivation therapy and side effects: are GnRH antagonists safer?. <i>Asian Journal of Andrology</i> , 2021 , 23, 3-10 | 2.8 | 3 |
| 290 | Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , 2021 , 12, 935 | 17.4 | 25 |
| 289 | Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. <i>Current Medical Research and Opinion</i> , 2021 , 37, 609-622 | 2.5 | 3 |
| 288 | Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. <i>Current Medical Research and Opinion</i> , 2021 , 37, 635-642 | 2.5 | 2 |
| 287 | A comparative study of PCS and PAM50 prostate cancer classification schemes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 733-742 | 6.2 | 2 |
| 286 | Use of psychotropic drugs among older patients with bladder cancer in the United States. <i>Psycho-Oncology</i> , 2021 , 30, 832-843 | 3.9 | 0 |
| 285 | Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 46-46 | 2.2 | 1 |
| 284 | Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. <i>Nature Communications</i> , 2021 , 12, 4362 | 17.4 | 8 |

| | | | |
|-----|---|------|----|
| 265 | Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 800-809 | 2.8 | 6 |
| 264 | Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 517-526 | 6.2 | 48 |
| 263 | Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 646-653 | 6.2 | 6 |
| 262 | INNV-12. A SINGLE-INSTITUTION RETROSPECTIVE REVIEW OF PATIENTS WITH CNS TUMORS WHO INITIATED A KETOGENIC DIET. <i>Neuro-Oncology</i> , 2020 , 22, ii118-ii119 | 1 | |
| 261 | 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2020 , 18, 671-684 | 6.6 | 18 |
| 260 | Treatment patterns in men with metastatic castration sensitive prostate cancer (mCSPC) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19131-e19131 | 2.2 | 4 |
| 259 | Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 346-346 | 2.2 | 1 |
| 258 | Veterans affairs (VA) prostate cancer treatment (Tx) sequencing (VAPCaTS): A real-world study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 54-54 | 2.2 | |
| 257 | Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020 , 46, 42-52 | 2 | 1 |
| 256 | Healthcare resource use (HRU) in men with metastatic castration sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT) only or no treatment in the United States (US).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19138-e19138 | 2.2 | 1 |
| 255 | Racial Discrepancies in Overall Survival among Men Treated with Radium. <i>Journal of Urology</i> , 2020 , 203, 331-337 | 2.5 | 14 |
| 254 | Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2020 , 204, 511-517 | 2.5 | 2 |
| 253 | Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy. <i>Urology</i> , 2020 , 137, 97-101 | 1.6 | 3 |
| 252 | Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. <i>BJU International</i> , 2020 , 125, 226-233 | 5.6 | 3 |
| 251 | Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1086-1093 | 12.9 | 10 |
| 250 | Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status: A Systematic Review and Meta-Analysis of Overall Survival Data. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 193-202 | 2.7 | 9 |
| 249 | Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 930.e13-930.e21 | 2.8 | 2 |
| 248 | Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020 , 6, 1912-1920 | 13.4 | 15 |

| | | | |
|-----|---|------|-----|
| 247 | Low Carbohydrate Diets in Men with Prostate Cancer May Reduce Risk of Cardiovascular Disease. <i>Current Developments in Nutrition</i> , 2020 , 4, 332-332 | 0.4 | 78 |
| 246 | Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. <i>European Urology</i> , 2020 , | 10.2 | 2 |
| 245 | Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2165-2170 | 4 | 2 |
| 244 | Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy. <i>Prostate</i> , 2020 , 80, 1244-1252 | 4.2 | 6 |
| 243 | Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. <i>Prostate</i> , 2020 , 80, 1304-1313 | 4.2 | 3 |
| 242 | Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 102-107 | 6.2 | 16 |
| 241 | Metabolomic effects of androgen deprivation therapy treatment for prostate cancer. <i>Cancer Medicine</i> , 2020 , 9, 3691-3702 | 4.8 | 8 |
| 240 | High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019 , 10, 4358 | 17.4 | 50 |
| 239 | A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 428-437 | 6.2 | 24 |
| 238 | Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 289.e11-289.e17 | 2.8 | 11 |
| 237 | Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019 , 5, 975-983 | 13.4 | 142 |
| 236 | Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. <i>European Urology</i> , 2019 , 76, 280-283 | 10.2 | 18 |
| 235 | Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. <i>JAMA Surgery</i> , 2019 , 154, e191629 | 5.4 | 16 |
| 234 | Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. <i>Cancer</i> , 2019 , 125, 3025-3032 | 6.4 | 2 |
| 233 | Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2019 , 125, 2861-2867 | 6.4 | 8 |
| 232 | Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 580-587 | 6.2 | 8 |
| 231 | Blood and dietary magnesium levels are not linked with lower prostate cancer risk in black or white men. <i>Cancer Letters</i> , 2019 , 449, 99-105 | 9.9 | 5 |
| 230 | Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy. <i>BJU International</i> , 2019 , 123, 91-97 | 5.6 | 7 |

| | | | |
|-----|--|-----|----|
| 229 | Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Cancer</i> , 2019 , 125, 4003-4010 | 6.4 | 10 |
| 228 | Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. <i>Prostate</i> , 2019 , 79, 1563-1571 | 4.2 | 7 |
| 227 | Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. <i>Cancer Epidemiology</i> , 2019 , 62, 101578 | 2.8 | 9 |
| 226 | Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e930-e938 | 3.3 | 0 |
| 225 | A Low Glycemic Index Diet Slows Prostate Cancer Growth (P05-018-19). <i>Current Developments in Nutrition</i> , 2019 , 3, | 0.4 | 78 |
| 224 | Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 633-635 | 6.2 | 6 |
| 223 | Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2019 , 2, 497-504 | 6.7 | 15 |
| 222 | Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5035-5035 | 2.2 | 4 |
| 221 | Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 372-372 | 2.2 | 0 |
| 220 | Racial disparities in radium-223 treatment in a large real-world population.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 268-268 | 2.2 | |
| 219 | Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2111-2111 | 2.2 | 1 |
| 218 | A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8-8 | 2.2 | |
| 217 | Radium-223 treatment patterns in a large real-world population.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 190-190 | 2.2 | |
| 216 | Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16021-e16021 | 2.2 | |
| 215 | Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi-STEPS).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS6651-TPS6651 | 2.2 | |
| 214 | Population-based outcomes comparing radical cystectomy with trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16029-e16029 | 2.2 | |
| 213 | A Clinician® Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). <i>Journal of Urology</i> , 2019 , 201, 682-692 | 2.5 | 38 |
| 212 | ACTR-15. PHASE 1 TRIAL OF A KETOGENIC DIET IN PATIENTS RECEIVING STANDARD-OF-CARE TREATMENT FOR RECENTLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi15-vi15 | 1 | 0 |

| | | | |
|-----|---|------|-----|
| 211 | Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6721-6730 | 12.9 | 35 |
| 210 | Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 711-716 | 2.7 | 2 |
| 209 | Nocturia and associated mortality: observational data from the REDUCE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 77-83 | 6.2 | 7 |
| 208 | Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 529-536 | 13.4 | 109 |
| 207 | Rapid Next-Generation Sequencing Method for Prediction of Prostate Cancer Risks. <i>Journal of Molecular Diagnostics</i> , 2019 , 21, 49-57 | 5.1 | 2 |
| 206 | Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?. <i>Cancer</i> , 2019 , 125, 434-441 | 6.4 | 2 |
| 205 | Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. <i>BJU International</i> , 2019 , 124, 69-75 | 5.6 | 8 |
| 204 | Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 292-302 | 6.2 | 8 |
| 203 | Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e140-e149 | 3.3 | 4 |
| 202 | The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 301-310 | 9.7 | 99 |
| 201 | Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019 , 75, 88-99 | 10.2 | 216 |
| 200 | Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>BJU International</i> , 2018 , 122, 592-598 | 5.6 | 7 |
| 199 | Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 783-789 | 4 | 1 |
| 198 | Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. <i>Cancer</i> , 2018 , 124, 3127-3135 | 6.4 | 23 |
| 197 | Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. <i>Cancer Causes and Control</i> , 2018 , 29, 581-588 | 2.8 | 18 |
| 196 | First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 239.e17-239.e25 | 2.8 | 9 |
| 195 | Prostate cancer: Race and prostate cancer personalized medicine: the future. <i>Nature Reviews Urology</i> , 2018 , 15, 207-208 | 5.5 | 5 |
| 194 | Individualizing PSA Monitoring Among Older Prostate Cancer Survivors. <i>Journal of General Internal Medicine</i> , 2018 , 33, 602-604 | 4 | 2 |

| | | | |
|-----|--|------|----|
| 193 | A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. <i>Journal of Urology</i> , 2018 , 199, 1459-1463 | 2.5 | 21 |
| 192 | Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 252-259 | 6.2 | 35 |
| 191 | Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018 , 31, 182-189 | 8.8 | 67 |
| 190 | Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>BJU International</i> , 2018 , 122, 76-82 | 5.6 | 6 |
| 189 | Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. <i>European Urology</i> , 2018 , 73, 168-175 | 10.2 | 39 |
| 188 | Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. <i>Journal of Urology</i> , 2018 , 199, 713-718 | 2.5 | 3 |
| 187 | Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE. <i>Journal of Urology</i> , 2018 , 199, 536-542 | 2.5 | 9 |
| 186 | Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. <i>Journal of Urology</i> , 2018 , 200, 758-766 | 2.5 | 27 |
| 185 | Robust genomic copy number predictor of pan cancer metastasis. <i>Genes and Cancer</i> , 2018 , 9, 66-77 | 2.9 | 5 |
| 184 | Re: Commentary on "The association between sexual function and prostate cancer risk in US veterans". <i>Asian Journal of Andrology</i> , 2018 , 20, 100 | 2.8 | |
| 183 | Overall survival of patients with metastatic prostate cancer starting androgen deprivation therapy with degarelix, a gonadotropin-releasing hormone antagonist.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 198-198 | 2.2 | |
| 182 | Predict: Evaluation of baseline characteristics predictive of distant metastases in patients with castration-resistant prostate cancer Updated data.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 253-253 | 2.2 | |
| 181 | Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2-2 | 2.2 | 1 |
| 180 | Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 382-382 | 2.2 | |
| 179 | Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17057-e17057 | 2.2 | 1 |
| 178 | Prevalence of residual tumor in the prostate after contemporary systemic therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17001-e17001 | 2.2 | |
| 177 | Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 106-112 | 6.2 | 2 |
| 176 | Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. <i>European Urology</i> , 2018 , 74, 107-114 | 10.2 | 36 |

| | | | |
|-----|---|------|-----|
| 175 | Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an AUA/ASTRO/SUO Guideline Summary. <i>Journal of Oncology Practice</i> , 2018 , 14, 618-624 | 3.1 | 11 |
| 174 | Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3251-3258 | 2.2 | 78 |
| 173 | ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. <i>Nature Medicine</i> , 2018 , 24, 1887-1898 | 50.5 | 63 |
| 172 | Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. <i>International Journal of Urology</i> , 2018 , 25, 1005 | 2.3 | 1 |
| 171 | Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. <i>International Journal of Urology</i> , 2018 , 25, 998-1004 | 2.3 | 5 |
| 170 | Enzalutamide treatment for the whole spectrum of CRPC. <i>Nature Reviews Urology</i> , 2018 , 15, 663-665 | 5.5 | 2 |
| 169 | The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme. <i>Journal of Urology</i> , 2018 , 200, 1062-1067 | 2.5 | 1 |
| 168 | PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 238-244 | 6.2 | 7 |
| 167 | Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 196-203 | 6.2 | 13 |
| 166 | Smoking and Death From Prostate Cancer. <i>JAMA Oncology</i> , 2018 , 4, 961-962 | 13.4 | 0 |
| 165 | A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. <i>European Urology</i> , 2018 , 74, 197-203 | 10.2 | 48 |
| 164 | Chronic Prostate Inflammation Predicts Symptom Progression in Patients with Chronic Prostatitis/Chronic Pelvic Pain. <i>Journal of Urology</i> , 2017 , 198, 122-128 | 2.5 | 28 |
| 163 | CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. <i>Cancer Research</i> , 2017 , 77, 1662-1673 | 10.1 | 56 |
| 162 | Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. <i>International Journal of Urology</i> , 2017 , 24, 151-156 | 2.3 | 5 |
| 161 | Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. <i>Scientific Reports</i> , 2017 , 7, 43551 | 4.9 | 6 |
| 160 | Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort. <i>Urology</i> , 2017 , 105, 129-135 | 1.6 | 12 |
| 159 | Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. <i>Journal of Urology</i> , 2017 , 198, 650-656 | 2.5 | 0 |
| 158 | Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017 , 3, 1663-1672 | 13.4 | 138 |

| | | | |
|-----|---|------|----|
| 157 | Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. <i>Prostate</i> , 2017 , 77, 446-457 | 4.2 | 13 |
| 156 | Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. <i>Cancer Prevention Research</i> , 2017 , 10, 319-326 | 3.2 | 16 |
| 155 | Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy. <i>Urology</i> , 2017 , 103, 161-166 | 1.6 | 9 |
| 154 | Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2017 , 123, 1528-1535 | 6.4 | 18 |
| 153 | Low-risk prostate cancer: to treat or not to treat. <i>Lancet Oncology, The</i> , 2017 , 18, 156-157 | 21.7 | 1 |
| 152 | Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. <i>Prostate</i> , 2017 , 77, 1592-1600 | 4.2 | 6 |
| 151 | Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017 , 8, 50804-50813 | 3.3 | 27 |
| 150 | Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1982-1990 | 2.2 | 56 |
| 149 | Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , | 3.3 | 6 |
| 148 | Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. <i>Urology</i> , 2017 , 108, 129-134 | 1.6 | 13 |
| 147 | Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 602.e1-602.e9 | 2.8 | 8 |
| 146 | Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. <i>Journal of Urology</i> , 2017 , 198, 1309-1315 | 2.5 | 9 |
| 145 | Response to Editorial Comment to Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. <i>International Journal of Urology</i> , 2017 , 24, 624-625 | 2.3 | |
| 144 | Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. <i>World Journal of Urology</i> , 2017 , 35, 1525-1530 | 4 | 1 |
| 143 | Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. <i>Cancer</i> , 2017 , 123, 4199-4206 | 6.4 | 24 |
| 142 | Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. <i>Cancer</i> , 2017 , 123, 4122-4129 | 6.4 | 13 |
| 141 | The current evidence on statin use and prostate cancer prevention: are we there yet?. <i>Nature Reviews Urology</i> , 2017 , 14, 107-119 | 5.5 | 79 |
| 140 | Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. <i>Prostate</i> , 2017 , 77, 154-163 | 4.2 | 17 |

| | | | |
|-----|--|------|-----|
| 139 | Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017 , 197, 122-128 | 2.5 | 29 |
| 138 | Limitations of the National Comprehensive Cancer Network (NCCN) Guidelines for Prediction of Limited Life Expectancy in Men with Prostate Cancer. <i>Journal of Urology</i> , 2017 , 197, 356-362 | 2.5 | 6 |
| 137 | In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. <i>European Urology Focus</i> , 2017 , 3, 480-486 | 5.1 | 4 |
| 136 | Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 60-66.e2 | 3.3 | 46 |
| 135 | Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 192-192 | 2.2 | 1 |
| 134 | Luminal and basal subtyping of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3-3 | 2.2 | 2 |
| 133 | Racial differences in prostate inflammation: results from the REDUCE study. <i>Oncotarget</i> , 2017 , 8, 71393-71399 | 3.3 | 99 |
| 132 | Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 133-133 | 2.2 | 1 |
| 131 | Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 142-142 | 2.2 | |
| 130 | Luminal and basal subtyping of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 2017, 3-3 | 2.2 | |
| 129 | Increased utilization of advanced imaging technology and its economic impact for patients diagnosed with bladder cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 368-368 | 2.2 | |
| 128 | Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16528-e16528 | 2.2 | |
| 127 | Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory post-hoc analysis of COU-AA-302 trial data.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16529-e16529 | 2.2 | |
| 126 | Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , 2016 , 17, 1612-1620 | 21.7 | 124 |
| 125 | Effect of body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. <i>Scientific Reports</i> , 2016 , 6, 19034 | 4.9 | 5 |
| 124 | Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. <i>Urology</i> , 2016 , 96, 171-176 | 1.6 | 38 |
| 123 | Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. <i>European Urology</i> , 2016 , 70, 588-596 | 10.2 | 56 |
| 122 | Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 303-11 | 3.5 | 18 |

| | | | |
|-----|--|------|----|
| 121 | Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 605-11 | 4 | 31 |
| 120 | ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS5087-TPS5087 | 2.2 | 11 |
| 119 | Association of baseline prostate atrophy with lower tumor volume in men with prostate cancer on repeat biopsy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 122-122 | 2.2 | |
| 118 | Association of chronic baseline prostate inflammation with lower tumor grade in men with prostate cancer on repeat biopsy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 75-75 | 2.2 | |
| 117 | Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 12-12 | 2.2 | |
| 116 | Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 76-76 | 2.2 | |
| 115 | Baseline subject characteristics to predict compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6-6 | 2.2 | |
| 114 | Does prostate inflammation on a negative prostate biopsy vary by race? Results from the REDUCE study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 116-116 | 2.2 | |
| 113 | Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4-4 | 2.2 | |
| 112 | Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. <i>Journal of Urology</i> , 2016 , 196, 1408-1414 | 2.5 | 37 |
| 111 | Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016 , 118, 570-7 | 5.6 | 7 |
| 110 | Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. <i>Journal of Urology</i> , 2016 , 196, 1493-1498 | 2.5 | 40 |
| 109 | Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted?. <i>BJU International</i> , 2016 , 117, 897-903 | 5.6 | 7 |
| 108 | Reply to Nicola Fossati, Giorgio Gandaglia, Alberto Bossi, Francesco Montorsi, Alberto Briganti@ Letter to the Editor re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy After Radical Prostatectomy. <i>European Urology</i> , 2016 , 70, 1408-1414 | 10.2 | |
| 107 | Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 547-54 | 4 | 10 |
| 106 | The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. <i>Journal of Urology</i> , 2016 , 196, 715-20 | 2.5 | 9 |
| 105 | Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. <i>European Urology</i> , 2016 , 69, 885-91 | 10.2 | 18 |
| 104 | Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. <i>Cancer</i> , 2016 , 122, 3848-3855 | 6.4 | 7 |

| | | | |
|-----|---|------|----|
| 103 | Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study. <i>Cancer Prevention Research</i> , 2015 , 8, 312-7 | 3.2 | 18 |
| 102 | Agent Orange and long-term outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 329.e1-6 | 2.8 | 3 |
| 101 | The association of exercise with both erectile and sexual function in black and white men. <i>Journal of Sexual Medicine</i> , 2015 , 12, 1202-10 | 1.1 | 12 |
| 100 | Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. <i>European Urology</i> , 2015 , 68, 1076-82 | 10.2 | 11 |
| 99 | Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. <i>Clinical Cancer Research</i> , 2015 , 21, 756-62 | 12.9 | 78 |
| 98 | Reply to M. Lee et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2226-7 | 2.2 | |
| 97 | Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. <i>Journal of Urology</i> , 2015 , 194, 1241-6 | 2.5 | 14 |
| 96 | Metformin use and risk of prostate cancer: results from the REDUCE study. <i>Cancer Prevention Research</i> , 2015 , 8, 1055-60 | 3.2 | 23 |
| 95 | Treatment patterns for older veterans with localized prostate cancer. <i>Cancer Epidemiology</i> , 2015 , 39, 769-77 | 2.8 | 9 |
| 94 | Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. <i>Journal of Urology</i> , 2015 , 193, 1232-8 | 2.5 | 10 |
| 93 | Smoking and Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2015 , 1, 28-38 | 5.1 | 26 |
| 92 | Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. <i>Cancer Epidemiology</i> , 2015 , 39, 1066-70 | 2.8 | |
| 91 | Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. <i>Scientific Reports</i> , 2015 , 5, 15341 | 4.9 | 13 |
| 90 | Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. <i>International Journal of Urology</i> , 2015 , 22, 658-62 ³ | | 8 |
| 89 | Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. <i>Prostate</i> , 2015 , 75, 1492-8 | 4.2 | 18 |
| 88 | Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. <i>Journal of Urology</i> , 2015 , 194, 52-7 | 2.5 | 2 |
| 87 | Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study. <i>Journal of Urology</i> , 2015 , 194, 1258-63 | 2.5 | 26 |
| 86 | Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator. <i>Journal of Urology</i> , 2015 , 193, 460-5 | 2.5 | 19 |

| | | | |
|----|--|------|-----|
| 85 | Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5016-5016 | 2.2 | |
| 84 | PREDICT, a study evaluating baseline (BL) disease characteristics predictive of a positive imaging study for distant metastases in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16028-e16028 | 2.2 | |
| 83 | A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. <i>European Urology</i> , 2014 , 66, 1054-64 | 10.2 | 120 |
| 82 | Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result. <i>Urology</i> , 2014 , 84, 1058-65 | 1.6 | 10 |
| 81 | Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2936-42 | 4 | 56 |
| 80 | Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2404-12 | 4 | 26 |
| 79 | Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. <i>Cancer</i> , 2014 , 120, 190-6 | 6.4 | 59 |
| 78 | Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2349-56 | 4 | 79 |
| 77 | The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. <i>Cancer Causes and Control</i> , 2014 , 25, 1029-35 | 2.8 | 23 |
| 76 | In reply to Berlin et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 240-1 | 4 | |
| 75 | Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. <i>Urology</i> , 2014 , 83, 599-605 | 1.6 | 2 |
| 74 | Obesity and long-term survival after radical prostatectomy. <i>Journal of Urology</i> , 2014 , 192, 1100-4 | 2.5 | 37 |
| 73 | Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. <i>European Urology</i> , 2014 , 66, 1133-8 | 10.2 | 20 |
| 72 | Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. <i>Journal of Urology</i> , 2014 , 192, 409-14 | 2.5 | 153 |
| 71 | Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. <i>European Urology</i> , 2014 , 65, 620-7 | 10.2 | 20 |
| 70 | Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. <i>European Urology</i> , 2014 , 65, 816-24 | 10.2 | 50 |
| 69 | Costs of radical prostatectomy for prostate cancer: a systematic review. <i>European Urology</i> , 2014 , 65, 316-24 | 10.2 | 69 |
| 68 | Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. <i>European Urology</i> , 2014 , 65, 1171-7 | 10.2 | 88 |

| | | | |
|----|--|------|-----|
| 67 | Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. <i>Journal of Oncology Practice</i> , 2014 , 10, e415-e417 | 3.1 | |
| 66 | Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3716-22 | 2.2 | 48 |
| 65 | Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. <i>Clinical Cancer Research</i> , 2014 , 20, 5331-8 | 12.9 | 22 |
| 64 | Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3892-8 | 2.2 | 69 |
| 63 | Impact of Comorbidity, Race, and Marital Status in Men Referred for Prostate Biopsy with PSA >20 ng/mL: A Pilot Study in High-Risk Patients. <i>International Scholarly Research Notices</i> , 2014 , 2014, 362814 | | 9 |
| 62 | Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. <i>European Urology</i> , 2014 , 65, 852-5 | 10.2 | 51 |
| 61 | The effect of diet and supplements on prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2014 , 12, 538-40 | 0.6 | |
| 60 | A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. <i>Cancer Prevention Research</i> , 2013 , 6, 1120-7 | 3.2 | 48 |
| 59 | Obesity and prostate cancer: weighing the evidence. <i>European Urology</i> , 2013 , 63, 800-9 | 10.2 | 337 |
| 58 | Association between family history of prostate cancer and positive biopsies in a Brazilian screening program. <i>World Journal of Urology</i> , 2013 , 31, 1273-8 | 4 | 3 |
| 57 | Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. <i>BJU International</i> , 2013 , 111, E310-8 | 5.6 | 11 |
| 56 | Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. <i>BJU International</i> , 2012 , 110, 492-8 | 5.6 | 65 |
| 55 | Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. <i>European Urology</i> , 2012 , 62, 757-64 | 10.2 | 95 |
| 54 | Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. <i>Urology</i> , 2012 , 80, 293-8 | 1.6 | 20 |
| 53 | Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Cancer</i> , 2012 , 118, 4999-5007 | 6.4 | 37 |
| 52 | African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4670-4670 | 2.2 | |
| 51 | The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. <i>Cancer Causes and Control</i> , 2011 , 22, 977-83 | 2.8 | 40 |
| 50 | Screening, risk assessment, and the approach to therapy in patients with prostate cancer. <i>Cancer</i> , 2011 , 117, 1123-35 | 6.4 | 74 |

| | | | |
|----|--|------|-----|
| 49 | Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 722-8 | 4 | 41 |
| 48 | Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 39-46 | 9.7 | 383 |
| 47 | Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 9-17 | 4 | 36 |
| 46 | Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. <i>Cancer Causes and Control</i> , 2010 , 21, 671-8 | 2.8 | 36 |
| 45 | Glycemic control and prostate cancer progression: results from the SEARCH database. <i>Prostate</i> , 2010 , 70, 1540-6 | 4.2 | 35 |
| 44 | Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. <i>Cancer</i> , 2009 , 115, 5263-71 | 6.4 | 61 |
| 43 | Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. <i>BJU International</i> , 2008 , 102, 969-74 | 5.6 | 39 |
| 42 | Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. <i>Journal of Urology</i> , 2008 , 179, 2181-5; discussion 2185-6 | 2.5 | 91 |
| 41 | The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. <i>Urology</i> , 2008 , 71, 151-5 | 1.6 | 13 |
| 40 | Obesity is a significant risk factor for prostate cancer at the time of biopsy. <i>Urology</i> , 2008 , 72, 1102-5 | 1.6 | 63 |
| 39 | Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. <i>Journal of Urology</i> , 2008 , 179, 1785-9; discussion 1789-90 | 2.5 | 16 |
| 38 | The influence of statin medications on prostate-specific antigen levels. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1511-8 | 9.7 | 126 |
| 37 | Rationale for statins in the chemoprevention of prostate cancer. <i>Current Prostate Reports</i> , 2008 , 6, 99-106 | | 1 |
| 36 | Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 63-9 | 4 | 264 |
| 35 | Radical prostatectomy for clinical stage T3a disease. <i>Cancer</i> , 2007 , 109, 1273-8 | 6.4 | 119 |
| 34 | Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. <i>Cancer</i> , 2007 , 110, 2202-9 | 6.4 | 55 |
| 33 | Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2275-80 | 27.4 | 255 |
| 32 | Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1765-71 | 2.2 | 140 |

| | | | |
|----|--|------|-----|
| 31 | Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. <i>Urology</i> , 2007 , 70, 277-82 | 1.6 | 41 |
| 30 | Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. <i>Journal of Urology</i> , 2006 , 176, 1404-8 | 2.5 | 101 |
| 29 | Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. <i>Journal of Urology</i> , 2006 , 175, 1298-302; discussion 1302-3 | 2.5 | 62 |
| 28 | Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. <i>Journal of Urology</i> , 2006 , 175, 500-4; discussion 504 | 2.5 | 136 |
| 27 | Prostate-specific antigen: update 2006. <i>Urology</i> , 2006 , 67, 458-60 | 1.6 | 22 |
| 26 | Update on outcomes research databases in prostate cancer 2006. <i>Current Opinion in Urology</i> , 2006 , 16, 168-72 | 2.8 | 6 |
| 25 | Are findings from studies of obesity and prostate cancer really in conflict?. <i>Cancer Causes and Control</i> , 2006 , 17, 5-9 | 2.8 | 83 |
| 24 | Serum leptin and pathological findings at the time of radical prostatectomy. <i>Journal of Urology</i> , 2005 , 173, 773-6 | 2.5 | 24 |
| 23 | Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. <i>Journal of Urology</i> , 2005 , 174, 919-22 | 2.5 | 83 |
| 22 | The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. <i>Journal of Urology</i> , 2005 , 174, 1276-81; discussion 1281; author reply 1281 | 2.5 | 59 |
| 21 | Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. <i>Journal of Urology</i> , 2005 , 174, 1266-70 | 2.5 | 57 |
| 20 | Obesity and prostate cancer. <i>Urology</i> , 2005 , 65, 433-9 | 1.6 | 38 |
| 19 | Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. <i>Urology</i> , 2005 , 65, 1131-6 | 1.6 | 28 |
| 18 | Body mass index as a predictor of prostate cancer: development versus detection on biopsy. <i>Urology</i> , 2005 , 66, 108-13 | 1.6 | 68 |
| 17 | Obesity and capsular incision at the time of open retropubic radical prostatectomy. <i>Journal of Urology</i> , 2005 , 174, 1798-801; discussion 1801 | 2.5 | 81 |
| 16 | Explaining racial differences in prostate cancer in the United States: sociology or biology?. <i>Prostate</i> , 2005 , 62, 243-52 | 4.2 | 102 |
| 15 | Obesity and prostate cancer: a growing problem. <i>Clinical Cancer Research</i> , 2005 , 11, 6763-6 | 12.9 | 50 |
| 14 | Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. <i>Clinical Cancer Research</i> , 2005 , 11, 2883-8 | 12.9 | 54 |

| | | | |
|----|--|------|-----|
| 13 | Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7546-54 | 2.2 | 186 |
| 12 | Can we preoperatively identify men who are at high risk for aggressive prostate cancer?. <i>Nature Reviews Urology</i> , 2005 , 2, 584-5 | | 1 |
| 11 | Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. <i>Clinical Cancer Research</i> , 2005 , 11, 7735-42 | 12.9 | 1 |
| 10 | Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 433-9 | 27.4 | 979 |
| 9 | Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 446-53 | 2.2 | 331 |
| 8 | Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. <i>Cancer</i> , 2004 , 100, 1633-8 | 6.4 | 34 |
| 7 | Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. <i>Cancer</i> , 2004 , 100, 1646-9 | 6.4 | 53 |
| 6 | Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. <i>Cancer</i> , 2004 , 101, 748-53 | 6.4 | 22 |
| 5 | Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. <i>Journal of Urology</i> , 2004 , 172, 520-4 | 2.5 | 79 |
| 4 | Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. <i>Journal of Urology</i> , 2004 , 171, 2215-20 | 2.5 | 42 |
| 3 | Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. <i>Journal of Urology</i> , 2004 , 171, 2260-4 | 2.5 | 108 |
| 2 | Do younger men have better biochemical outcomes after radical prostatectomy?. <i>Urology</i> , 2004 , 63, 518-22 | | 53 |
| 1 | Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. <i>Urology</i> , 2004 , 63, 887-91 | 1.6 | 5 |